文献速递淋巴瘤白血病

人类T淋巴细胞病毒1型感染及向成人T细胞白血病或淋巴瘤进展的分子与免疫综合特征

Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma.
PubMed 文献 · Lancet Haematol · 2023-01-01

本文综述人类T淋巴细胞病毒1型(HTLV-1)感染及向成人T细胞白血病或淋巴瘤(ATLL)进展的分子与免疫特征,提出四阶段疾病模型:病毒暴露、慢性感染建立、细胞转化与演化、疾病表现与管理,并讨论各阶段临床特征、潜在生物标志物及治疗靶点。

要点

  • ATLL总体生存期依亚型为8至55个月,目前HTLV-1无预防或治愈手段。
  • 作者提出四阶段疾病模型以聚焦HTLV-1与ATLL的治疗研发。

核心结论

  • 作者提出HTLV-1相关ATLL的四阶段疾病模型,希望推动对这一被忽视病毒及其相关罕见癌症的治疗研究。

研究设计与样本

  • 综述类文章,检索范围未在原文中报告。

主要发现

  • HTLV-1感染导致终身感染和免疫抑制,5%的病例发生ATLL。
  • ATLL总体生存期依疾病亚型为8至55个月。
  • 过去十年已识别HTLV-1感染及进展至ATLL过程中的遗传、分子和免疫事件。
  • 作者构建四阶段疾病模型:病毒暴露、慢性感染建立、细胞转化与演化、疾病表现与管理。

关键数值与推荐

  • 各阶段描述了临床特征、涉及的分子与免疫因素、疾病进展的潜在生物标志物及个体靶点的治疗适用性。
  • 已发表更新的临床管理指南。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The human T-lymphotropic virus type 1 (HTLV-1) retrovirus infects 10-20 million people globally, with endemic regions in southwestern Japan, the Caribbean basin, Africa, and central Australia. HTLV-1 is associated with lifelong infection and immune suppression, resulting in a range of serious sequalae, including adult T-cell leukaemia or lymphoma (ATLL) in 5% of cases. To date, there are no preventive or curative treatments for HTLV-1 and treatment outcomes for ATLL remain generally poor. Depending on the disease subtype, overall survival is 8-55 months. Recent advancements in the past decade have identified genetic, molecular, and immunological events occurring throughout the lives of individuals infected with HTLV-1 and of those who progress to ATLL. In addition, updated guidelines for clinical management have been published. With the aim of focusing research efforts on the development of treatments for both HTLV-1 infections and ATLL, we have conceptualised a four-step disease model for HTLV-1-associated ATLL: (1) viral exposure, (2) establishment of chronic infection, (3) cellular transformation and evolution, and (4) disease presentation and management. For each stage we describe the clinical features, molecular and immunological factors involved, potential biomarkers of disease progression, and the therapeutic applicability of individual targets. We also discuss emerging concepts and novel treatment approaches. Our hope is that this model will promote research interest and guide the testing of new treatments for this neglected virus and its associated rare cancer.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. O'Donnell JS, Hunt SK, Chappell KJ, et al. Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. Lancet Haematol. 2023. PMID: 37407143. doi:10.1016/S2352-3026(23)00087-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。